A retrospective study analysing Risk factors for myocarditis associated with immune checkpoint inhibitors and/or the PD1/PDL1 alone or in combination with ICI and/or chemotherapy
Latest Information Update: 11 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
- Indications Cancer
- Focus Adverse reactions
- 11 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology